Vitamin D deficiency and anemia in early chronic kidney disease  by Patel, Neha M. et al.
Vitamin D deficiency and anemia in early chronic
kidney disease
Neha M. Patel1, Orlando M. Gutie´rrez1, Dennis L. Andress2, Daniel W. Coyne3, Adeera Levin4 and
Myles Wolf1
1Division of Nephrology and Hypertension, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA;
2Abbott Laboratories, Research and Development, Abbott Park, Illinois, USA; 3Renal Division, Department of Medicine, Washington
University, St Louis, Missouri, USA and 4Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver,
British Columbia, Canada
Vitamin D has a number of pleiotropic effects in a variety of
tissues, in addition to its well-known effects on mineral
metabolism. To determine whether it has an effect on
erythropoiesis, we studied the association of the components
of the vitamin D axis with the prevalence and severity of
anemia in chronic kidney disease. We measured the
concentrations of 25-hydroxyvitamin D (25D), 1,25-
dihydroxyvitamin D (1,25D), and hemoglobin in a cross-
sectional study of 1661 subjects in SEEK, a multi-center
cohort study of chronic kidney disease patients in the United
States, of whom 41% met the criteria for anemia. The mean
hemoglobin concentrations significantly decreased with
decreasing tertiles of 25D and 1,25D. These linear trends
remained significant after adjustment for age, gender,
ethnicity, eGFR, diabetes, and parathyroid hormone. In
similarly adjusted models, the lowest tertiles of 25D and
1,25D were independently associated with 2.8- and 2.0-fold
increased prevalence of anemia compared with their
respective highest tertiles. Patients with severe dual
deficiency of 25D and 1,25D had a 5.4-fold prevalence of
anemia compared with those replete in both. Our study
shows that 25D and 1,25D deficiency are independently
associated with decreased hemoglobin levels and anemia in
chronic kidney disease. Whether this association is causal
requires further study.
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Chronic kidney disease (CKD) afflicts over 20 million people
in the United States.1 With growing incidence of diabetes
mellitus and an aging population, CKD is increasing in
incidence and prevalence, and patients continue to suffer
from a variety of complications ranging from volume
overload and electrolyte imbalances to disordered mineral
and bone metabolism and anemia.1–3 Although principal
causes of CKD-associated anemia include erythropoietin
deficiency, iron deficiency, and malnutrition–inflammation,
recent studies suggest a potential effect of deficiencies in the
vitamin D axis as an additional pathophysiological factor.4–6
In vitro studies of bone marrow red cell precursor cells
demonstrate that calcitriol (1,25-dihydroxyvitamin D
(1,25D)) increases erythropoietin-receptor expression and
synergistically stimulates proliferation along with erythro-
poietin.7 In vivo and in vitro studies suggest that 1,25D
directly affects the proliferation of erythroid precursors via
increased membrane permeability of calcium.8,9 In addition,
vitamin D has anti-inflammatory actions that could theore-
tically improve erythropoietin responsiveness, perhaps by
reducing interleukin-6 (IL-6) levels and thus levels of
hepcidin, an acute-phase reactant that is a key negative
regulator of iron absorption and utilization that is also
significantly elevated in CKD.10,11 Finally, extremely high
parathyroid hormone (PTH) levels have been considered a
mechanism for decreased erythropoiesis via increased bone
marrow fibrosis and erythropoietin resistance in CKD
patients.12,13 Whether this represents exclusively a direct
antagonistic effect of PTH on erythropoiesis or could be
partially owing to the low 1,25D levels that accompany high
PTH in dialysis patients, is unknown because vitamin D
levels were not measured in the studies that examined PTH
and anemia.4,14 Indeed, previous studies have suggested
improved control of anemia in dialysis patients treated with
active forms of vitamin D such as calcitriol or nutritional
vitamin D precursors such as ergocalciferol.13,15–17
Given these associations, the high prevalence of anemia
and 25-hydroxyvitamin D (25D) and 1,25D deficiency in
CKD, and the abundant availability of therapies for
correcting these deficiencies, we undertook a cross-sectional
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analysis of a cohort of pre-dialysis CKD patients to test the
hypothesis that deficiencies in the vitamin D axis, both 25D
and 1,25D, are independently associated with lower hemoglobin
levels and higher prevalence of anemia in early CKD.
RESULTS
Subject characteristics
In the overall study sample, the mean age was 70±11 years,
mean estimated glomerular filtration rate (eGFR) was
47±18ml/min/1.73m2, and mean hemoglobin was
13±2 g/dl. The criteria for anemia (hemoglobin o13.5 g/dl
for men and o12 for women) were met by 41% of subjects.
The clinical and demographic characteristics of anemic
versus non-anemic subjects are compared in Table 1.
Compared with non-anemic subjects, anemic subjects were
more likely to be Black, older males, with a history of
diabetes, congestive heart failure, and hypertension, and
were more likely to have been treated with angiotensin-
converting enzyme inhibitors (ACE inhibitors) and angio-
tensin-II receptor blockers (ARBs). In addition, anemic
subjects had lower GFR, serum albumin, calcium, 25D, and
1,25D, and higher serum phosphorus and PTH than non-
anemic subjects. While median IL-6 levels were significantly
higher in the anemic patients as compared with that in the
non-anemic group (3.6 pg/ml, interquartile range: 2.6–5.7
versus 3.0 pg/ml, interquartile range: 2.2–4.5; P¼ 0.004),
there was no significant difference between the median
C-reactive protein (CRP) levels in anemic versus non-anemic
patients (2.7mg/l, interquartile range: 1.2–7.9 versus 2.8mg/l,
interquartile range: 1.2–6.4; P¼ 0.67).
Relationship between vitamin D levels and hemoglobin
concentration
There was a linear relationship between hemoglobin
concentration and both 25D (r¼ 0.22; Po0.001) and
1,25D (r¼ 0.26; Po0.001) concentrations. Mean hemoglo-
bin concentrations decreased with decreasing tertiles of 25D
and 1,25D (Table 2). In multivariable linear regression model
adjusted for age, sex, race, eGFR, diabetes, and PTH, there
was a stepwise decrease in hemoglobin concentrations with
decreasing tertiles of 25D (Table 2). Interestingly, the
magnitude of effect was greatest among subjects who had
dual deficiency of both vitamin D metabolites—subjects with
severe deficiency of both forms of vitamin D (25D o10 ng/
ml and 1,25D o30 pg/ml) had a multivariable-adjusted 8%
lower hemoglobin concentration when compared with
subjects who had the highest concentrations of both 25D
(430 ng/ml) and 1,25D (45 pg/ml). Furthermore, multi-
variate analyses adjusted for all other covariates in addition to
both vitamin D metabolites simultaneously showed inde-
pendent effects of 25D and 1,25D on hemoglobin concentra-
tion (Po0.001 for both).
Table 1 | Characteristics of the study population by anemia
status
Characteristic Anemic Non-anemic P-value
n 680 981
Age (years) 71±11 69±11 0.003
Female gender (%) 41 60 o0.001
Black race (%) 17 8 o0.001
Body mass index (kg/m2) 31±7 31±7 0.53
Blood pressure (mmHg)
Systolic 132±18 131±17 0.26
Diastolic 71±9 74±11 o0.001
Estimated GFR (ml/min/1.73m2) 41±16 52±17 o0.001
Chronic kidney disease stage (%)
2 (eGFR 460) 12 31 o0.001
3 (eGFR 30–59) 62 59 o0.001
4 (eGFR 15–29) 23 9 o0.001
5 (eGFR o15) 3 1 o0.001
Laboratory results
Hemoglobin, men (g/dl) 12±1 15±1 o0.001
Hemoglobin, women (g/dl) 11±0.8 13±1 o0.001
25D (ng/ml) 26±13 31±12 o0.001
1,25D (pg/ml) 24 (15, 33) 32 (22, 45) o0.001
Albumin (g/dl) 4.1±0.4 4.3±0.3 o 0.001
Calcium (mg/dl)a 9.1±0.5 9.2±0.4 o0.001
Phosphorus (mg/dl) 3.8±0.7 3.6±0.6 o0.001
PTH (pg/ml) 68 (42, 114) 50 (33, 78) o0.001
Co-morbidities (%)
Diabetes mellitus 58 42 o0.001
Hypertension 92 83 o0.001
Congestive heart failure 26 15 o0.001
Medications
ACE inhibitor 44 34 o0.001
ARB 37 32 0.03
Abbreviations: 25D, 25-hydroxyvitamin D; 1,25D, calcitriol/1,25-dihydroxyvitamin D;
ACE, angiotensin-converting enzyme; ARB, angiotensin-II-receptor blocker; eGFR,
estimated glomerular filtration rate; PTH, parathyroid hormone.
Anemia was defined as a hemoglobin value of o13.5 g/dl for men and o12 g/dl
for women.
aCorrected for serum albumin.
Table 2 |Mean hemoglobin concentrations by tertiles of 25D
and 1,25D, and multivariable-adjusteda D-hemoglobin








n 52 911 708
Mean hemoglobin
(g/dl)
11.7±2 12.8±2 13.5±2 o0.001








n 897 456 308
Mean hemoglobin
(g/dl)
12.7±2 13.3±2 13.7±2 o0.001
D Hemoglobin (%) 3% 2% Reference o0.01
Abbreviations: 25D, 25-hydroxyvitamin D; 1,25D, calcitriol/1,25-dihydroxyvitamin D;
BMI, body mass index; eGFR, estimated glomerular filtration rate; PTH, parathyroid
hormone.
aAdjusted for age, race, gender, eGFR, diabetes, hypertension, BMI, PTH.
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Relationship between vitamin D levels and prevalence
of anemia
The lowest tertiles of 25D and 1,25D were associated with the
highest prevalence of anemia, and the middle tertiles of each
were associated with an intermediate prevalence (Figure 1a). In
multivariable-adjusted logistic regression models (Figure 1b),
the lowest tertile of 25D was associated with 2.8-fold increased
prevalence of anemia (95% confidence interval 1.5–5.1)
compared with the highest, while the lowest tertile of 1,25D
was associated with 2.0-fold increased prevalence of anemia
(95% confidence interval 1.5–2.9) compared with the highest
tertile. Additionally, subjects with severe deficiency of both
forms of vitamin D (25D o10 ng/ml and 1,25D o30 pg/ml)
had the greatest prevalence of anemia compared with subjects
with a deficiency in a single vitamin D metabolite or those with
sufficient levels of both (Figure 2). In the corresponding
multivariable analysis, subjects with severe dual deficiency of
both vitamin D metabolites had a 5.4-fold increased prevalence
of anemia (95% confidence interval 1.9, 15.1) compared with
subjects who had both 25D levels above 30 ng/ml and 1,25D
levels above 45 pg/ml.
Effect of renal function, gender, medication use, and
markers of inflammation
The independent associations between vitamin D concentra-
tions (both 25D and 1,25D) and hemoglobin concentrations
were consistent across all stages of CKD—when adjusting for
residual confounding of eGFR, all subsets of the CKD
population under study demonstrated a graded, stepwise
decrease in hemoglobin levels and increased prevalence of
anemia with decreasing vitamin D levels. The results were not
modified by gender or by use of ACE inhibitors or ARBs
(data not shown).
In a secondary analysis of the 370 subjects with available
measurements of CRP and IL-6, the effects of 25D and 1,25D
on hemoglobin concentration and prevalence of anemia
remained significant after adjusting for the inflammatory
biomarkers.
DISCUSSION
In this cross-sectional study, we observed a linear relationship
between vitamin D and hemoglobin concentrations. There
was a stepwise decrease in hemoglobin concentrations and a
stepwise increase in the prevalence of anemia with decreasing
tertiles of vitamin D concentrations that persisted in
multivariable analyses. Furthermore, there was an additive
effect of dual deficiency of 25D and 1,25D on the prevalence
of anemia. Each of these associations was independent of
multiple potential confounding factors and was not modified
by gender, use of ACE inhibitors, or ARBs, or inflammatory
markers such as CRP and IL-6. Collectively, these data
suggest that deficiencies in the vitamin D axis are potential
novel risk factors for anemia in CKD. Although causality can
only be determined through confirmatory longitudinal
observational and subsequent interventional studies, the
results suggest that an additional pleiotropic benefit of
vitamin D therapy in CKD might be to attenuate anemia and
improve sensitivity to erythropoietin.
The results of this study are consistent with previous
studies of dialysis patients in which vitamin D supplementa-
tion with ergocalciferol and calcitriol appeared to increase
sensitivity to erythropoietin as evidenced by a lower
requirement for erythropoiesis-stimulating agents to achieve
similar control of anemia.13,15–17 Additionally, in a recent


















































































Figure 1 |Prevalence and odds ratios of anemia according to tertiles of 25D and 1,25D. (a) Prevalence of anemia by tertiles of 25D
and 1,25D. (b) Multivariable-adjusted odds ratios of anemia by tertiles of 25D and 1,25D. *Po0.05 compared with the highest tertile.



















Figure 2 | The combined effects of lowest 25D and 1,25D
levels on the prevalence of anemia. *Po0.01 compared with
the high 25D and high 1,25D group.
Kidney International (2010) 77, 715–720 717
NM Patel et al.: Vitamin D deficiency and anemia in early CKD o r ig ina l a r t i c l e
Nutrition Examination Study (NHANES III), lower 25D
levels were independently associated with lower hemoglobin
concentrations within the CKD population.6 We confirm
these results in this study, but also extend them in two
important ways. First, unlike the NHANES study, we were
able to further adjust for PTH levels and data points
regarding treatment with ACE inhibitors, and ARBs, that
were not available in NHANES III. While it is encouraging
that the results remained significant, by observing an
association that is independent of PTH, we can speculate
that at least a portion of the erythropoietin resistance
historically attributed to marked increases in PTH may in
fact relate to deficiencies in the vitamin D axis that were not
assessed in previous studies. Second, unlike previous reports,
we were able to assess 1,25D concentrations and demonstrate
their independent association with anemia as well. Further-
more, the seemingly additive effect of a combination of 25D
and 1,25D deficiency, that is, global deficiency in the vitamin
D axis, lends overall support for the role of the vitamin D axis
in contributing to normal erythropoiesis in this population.
Cardiovascular disease is highly prevalent in the CKD
population when compared with the general population and
remains the leading cause of death.18 In addition to
traditional risk factors, deficiencies in the vitamin D axis
and anemia have also been implicated in the excessive
cardiovascular risk associated with CKD.19 Interestingly, one
of the main cardiovascular disease phenotypes that is strongly
linked to mortality and that is associated with both
deficiencies in the vitamin D axis and anemia, is left
ventricular hypertrophy.20,21 Thus, it is interesting to
speculate whether there could be mechanistic overlap
between the two, and whether vitamin D therapy used as
an adjunct to traditional anemia management might together
improve outcomes by attenuating cardiovascular risk.
Although a number of clinical trials have failed to
demonstrate a reduction in cardiovascular risk in response
to anemia management in CKD,22,23 observational studies
have demonstrated clear links between higher hemoglobin
levels and improved survival in the CKD population.24–26
There are several important limitations to this study. Due
to the study’s cross-sectional design, it is not possible to
determine a causal relationship between vitamin D deficiency
and anemia. In addition, data on iron stores and treatment
with erythropoiesis stimulating agents (ESAs) were unavail-
able. However, previous studies that did correct for ESA
use13,15 and iron stores6 found similar results. Furthermore,
it is unlikely that more than a small proportion of this
population of CKD patients, most of which had early stages
of CKD and was largely recruited from primary care and
family practices, would have been on ESAs during the
study. We did have data on CRP and IL-6 for a subset
of patients, and the relationship between vitamin D and
hemoglobin concentrations remained significant after adjust-
ing for these indices. Due to the small sample size of this
exploratory analysis, additional studies with larger numbers
of participants are needed to further examine the potential
relationships between vitamin D, inflammation, iron utilization,
and erythropoiesis.
Given the high prevalence of anemia and deficiencies in
the vitamin D axis in patients with CKD, and the ease and
low cost of correcting these deficiencies, this study in the
context of other findings and biological plausibility suggests a
potential additional benefit to early vitamin D treatment as
an adjunct to traditional anemia management. Since both
25D and 1,25D deficiency are independently associated with
lower hemoglobin concentration, future studies should
explore the relative erythropoiesis-stimulating effects of
nutritional vitamin D supplements and active forms of
vitamin D, alone and in combination.
MATERIALS AND METHODS
Study population
The Study to Evaluate Early Kidney Disease (SEEK) was a multi-
center, descriptive study designed to assess the timing and severity of
disordered mineral metabolism across the spectrum of CKD.27
Patients greater than 40 years of age with an established healthcare
provider and a screening eGFR o60ml/min/1.73m2 as determined
by the Modification of Diet in Renal Disease equation,28 were
eligible for enrollment. The eGFR was recalculated at the subsequent
study visit; hence some subjects had eGFR 460ml/min/1.73m2 on
repeat testing but remained in the study. The exclusion criteria
included renal replacement therapy, a history of primary parathyr-
oid disease, or use of prescription-based vitamin D supplementation
within 12 months of screening. A total of 1,814 eligible patients were
recruited from 153 centers across all regions of the United States.
Study visits were conducted during peak sunlight season between
June 2004 and October 2004, thereby minimizing confounding due
to seasonal variations in sun exposure. Of the 1,814 patients
included in the SEEK study, 153 were excluded because of missing
data on 25D, 1,25D, or hemoglobin concentrations, leaving 1,661
patients in the final study sample.
Variables of interest
The key variables of interest for this study were hemoglobin, 25D, and
1,25D. The primary outcome was presence of anemia, defined as
hemoglobin o13.5 g/dl for men and o12 g/dl for women.29 The
primary predictors were 25D and 1,25D levels, which were measured
using DiaSorin radioimmunoassay kits (Stillwater, MN, USA). 25D
deficiency was defined as a level of o30ng/ml, while severe 25D
deficiency was defined as a level of o10ng/ml as has been done
previously.19 Since normal ranges for 1,25D are not clearly established,
we analyzed the tertiles of 1,25D levels according to their distribution in
subjects with sufficient renal function (eGFR 460ml/min/1.73m2).
We defined the lowest tertile as 1,25D deficient (o30pg/ml) and the
uppermost tertile of 1,25D as 445pg/ml.
Covariates included age, gender, race, body mass index, blood
pressure, laboratory tests (eGFR, calcium, phosphorus, parathyroid
hormone), co-morbidities (diabetes mellitus, hypertension, con-
gestive heart failure), and medication use (ACE inhibitors, ARBs).
All samples were analyzed at a central laboratory (Quintiles
Laboratories Ltd, Parsippany, NJ, USA) by technicians who were
blinded to clinical and demographic data. Calcium, phosphorus,
and creatinine levels were quantified with a standard autoanalyzer.
Total calcium was corrected for serum albumin using the following
formula: Calcium¼Caþ 0.8 (4.0Albumin) when albumin was
718 Kidney International (2010) 77, 715–720
or ig ina l a r t i c l e NM Patel et al.: Vitamin D deficiency and anemia in early CKD
less than 4.0 g/dl. Intact PTH was quantified with a chemilumines-
cence assay (DPC, Los Angeles, CA, USA).
Statistical analyses
The clinical and demographic data were compared between anemic
and non-anemic subjects using Student’s t-test, Wilcoxon’s rank-
sum test, or w2-test as appropriate. Linear regression models were
used to examine the relationships between vitamin D and
hemoglobin concentration. We used multivariable models to adjust
for age, gender, race, eGFR, diabetes, hypertension, body mass
index, and PTH. Univariable- and multivariable-adjusted logistic
regression models were used to examine the association between
vitamin D levels and prevalence of anemia. In all models, vitamin D
concentrations were examined on a continuous scale, and also
categorically in tertiles. To investigate whether there were additive
effects of 25D and 1,25D deficiency on hemoglobin concentrations
and prevalence of anemia, we repeated the multivariable analyses
after creating four groups of subjects based on the permutations of
presence or absence of severe 25D (o10 ng/ml) and 1,25D (o30 pg/
ml) deficiency. To investigate the independent effects of 25D and
1,25D deficiency on hemoglobin concentration, we performed
additional multivariable-adjusted analyses including all other
covariates plus both vitamin D metabolites simultaneously.
To investigate whether the effects of vitamin D levels on
hemoglobin were independent of renal function, we performed
additional stratified analyses within individual stages of CKD. We
also adjusted for use of ACE inhibitors and ARBs in further analyses
given prior reports of increased human erythropoietin requirements
in hemodialysis patients prescribed ACE inhibitors and/or
ARBs.30,31 Finally, we performed a secondary exploratory analysis
of the effect brought on the association between vitamin D levels
and anemia by the markers of inflammation, CRP and IL-6, which
were available in a subset of 370 subjects. All statistical analyses
were performed using SAS software, version 9.1 (SAS Institute,
Cary, NC, USA), and a P-value o0.05 was considered statistically
significant.
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